Health Risks of Ionizing Radiation: - Clark University
Health Risks of Ionizing Radiation: - Clark University
Health Risks of Ionizing Radiation: - Clark University
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ii Contents<br />
Thorotrast ............................................................................................................. 24<br />
3.3 Radiotherapy for non-cancer disease .......................................................................... 24<br />
Tuberculosis ......................................................................................................... 25<br />
Ankylosingspondylitis ......................................................................................... 25<br />
Hyperthyroidism .................................................................................................. 26<br />
Radiotherapy for other non-cancer diseases ........................................................ 26<br />
Radiotherapy for non-cancer disease in children ................................................. 26<br />
3.4 Radiotherapy for cancer ............................................................................................. 28<br />
Radiotherapy for childhood cancer ...................................................................... 29<br />
3.5 In utero exposures ....................................................................................................... 29<br />
3.6 Parental exposures ...................................................................................................... 30<br />
3.7 Radiologists’ occupational exposures ......................................................................... 31<br />
3.8 Conclusions ................................................................................................................ 31<br />
4. ATOMIC BOMB SURVIVORS ........................................................................................ 43<br />
4.1 Introduction ................................................................................................................ 43<br />
RERF research ..................................................................................................... 43<br />
Doses .................................................................................................................... 44<br />
Uncertainties ........................................................................................................ 45<br />
4.2 Cancer mortality ......................................................................................................... 45<br />
4.3 Noncancer mortality ................................................................................................... 48<br />
4.4.1 Solid cancer incidence ................................................................................................ 48<br />
4.4.2 Incidence <strong>of</strong> leukemia and related cancers ................................................................. 49<br />
4.5 Incidence <strong>of</strong> noncancer disease .................................................................................. 50<br />
4.6 Preconception and prenatal exposures ........................................................................ 51<br />
4.7 Discussion ................................................................................................................... 52<br />
Age, time and gender ........................................................................................... 52<br />
Dose-response curves ........................................................................................... 52<br />
Applicability to other contexts ............................................................................. 53<br />
5. NUCLEAR WEAPONS TESTING .................................................................................. 58<br />
5.1 Military personnel ...................................................................................................... 58<br />
5.2 Semipalatinsk Test Site downwinders ........................................................................ 59<br />
5.3 Nevada Test Site downwinders ................................................................................... 60<br />
Leukemia .............................................................................................................. 60<br />
Thyroid disease .................................................................................................... 61<br />
5.4 South Pacific testing ................................................................................................... 63<br />
5.5 <strong>Health</strong> effects in Scandinavia ..................................................................................... 63<br />
5.6 Discussion ................................................................................................................... 63<br />
6. RADIATION WORKERS ................................................................................................. 70<br />
6.1 Introduction ................................................................................................................ 70<br />
Exposure limits .................................................................................................... 70<br />
Assessing risks ..................................................................................................... 72<br />
6.2 US facilities ................................................................................................................ 73<br />
Hanford ................................................................................................................ 73<br />
Oak Ridge ............................................................................................................ 75<br />
Oak Ridge and age at exposure ............................................................................ 76<br />
Rocketdyne .......................................................................................................... 77